Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CRIS)

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire April 5, 2024

Curis to Present at Upcoming Healthcare Conferences in April

PR Newswire April 4, 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)

PR Newswire April 2, 2024

Curis Provides Fourth Quarter 2023 Business Update

PR Newswire February 8, 2024

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

PR Newswire February 1, 2024

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 5, 2024

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

PR Newswire December 12, 2023

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

PR Newswire December 11, 2023

Curis Announces Three Presentations at ASH

PR Newswire December 6, 2023
View More News ››

Opinion & Analysis (NDAQ:CRIS)

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Streetwise Reports June 11, 2020
View More Opinion ››

Bullboard Posts (NDAQ:CRIS)

Buy Recommendation Issued On CRIS By Piper Sandler

JUST IN: $CRIS Buy Recommendation Issued On CRIS By Piper Sandler2024-02-09 10:15:03 ET Piper Sandler analyst issues BUY recommendation...
whytestocks - February 9, 2024

should be a good year here

for this stock,so glta.
coolfooldumbguy - March 31, 2019

it's a buy today for me

it looks like it will perform this year,so glta.
coolfooldumbguy - March 25, 2019

STELLAR RESULTS!

Curis Reports First Quarter 2016 Financial Results CRIS | 49 minutes ago  ...
Interpolation1 - May 9, 2016

CURIS PRESENTING IN JUST OVER A WEEK!

Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual...
Interpolation1 - April 11, 2016

Phase 1 results are in and are encouraging!

http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=83998951&cp=off&webmasterId=101442
Interpolation1 - April 4, 2016
View more Bullboard ››

Centurion Minerals Ltd

Centurion Minerals Ltd

View More »